- Home
- MGNX vs BMGL Comparison
MGNX vs BMGL Comparison
Compare MGNX & BMGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- BMGL
- Stock Information
- Founded
- MGNX 2000
- BMGL 2001
- Country
- MGNX United States
- BMGL Singapore
- Employees
- MGNX N/A
- BMGL N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- BMGL
- Sector
- MGNX Health Care
- BMGL
- Exchange
- MGNX Nasdaq
- BMGL NYSE
- Market Cap
- MGNX 70.3M
- BMGL 75.9M
- IPO Year
- MGNX 2013
- BMGL 2025
- Fundamental
- Price
- MGNX $1.26
- BMGL $4.45
- Analyst Decision
- MGNX Hold
- BMGL
- Analyst Count
- MGNX 10
- BMGL 0
- Target Price
- MGNX $6.83
- BMGL N/A
- AVG Volume (30 Days)
- MGNX 1.1M
- BMGL 141.3K
- Earning Date
- MGNX 05-08-2025
- BMGL 01-01-0001
- Dividend Yield
- MGNX N/A
- BMGL N/A
- EPS Growth
- MGNX N/A
- BMGL 16.23
- EPS
- MGNX N/A
- BMGL 0.09
- Revenue
- MGNX $149,962,000.00
- BMGL $7,428,776.00
- Revenue This Year
- MGNX N/A
- BMGL N/A
- Revenue Next Year
- MGNX $80.86
- BMGL N/A
- P/E Ratio
- MGNX N/A
- BMGL $47.29
- Revenue Growth
- MGNX 155.26
- BMGL 3.32
- 52 Week Low
- MGNX $0.99
- BMGL $3.63
- 52 Week High
- MGNX $17.24
- BMGL $5.50
- Technical
- Relative Strength Index (RSI)
- MGNX 34.84
- BMGL N/A
- Support Level
- MGNX $1.10
- BMGL N/A
- Resistance Level
- MGNX $1.34
- BMGL N/A
- Average True Range (ATR)
- MGNX 0.13
- BMGL 0.00
- MACD
- MGNX 0.04
- BMGL 0.00
- Stochastic Oscillator
- MGNX 77.14
- BMGL 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.